Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With
One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
How well does cabozantinib works in combination with nivolumab and ipilimumab in treating
patients with rare genitourinary (GU) tumors that have spread to other places in the
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II trial studies how well cabozantinib works in combination with nivolumab
and ipilimumab in treating patients with rare genitourinary (GU) tumors that have
spread to other places in the body. Cabozantinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread.
Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients
with genitourinary tumors that have no treatment options compared to giving cabozantinib,
nivolumab, or ipilimumab alone.
Study Reference #: CGUM19070
Lead Researcher (Principal Investigator)
Lead Researcher: Adrienne Victor
Study Contact InformationStudy Coordinator: Park Bogan
Phone: (585) 276-4415
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search